首页 › 基金 › Bellevue Group AG › VRDN
Bellevue Group AG 对 VRDN 的持仓历史
VIRIDIAN THERAPEUTICS INC · 医疗保健
Bellevue Group AG 在 Q3 2026 的 13F 申报中披露持有 VRDN(VIRIDIAN THERAPEUTICS INC)7,109,318 股,市值约 US$146.4M,约占其申报组合的 3.04%,在其申报持仓中市值排名第 8 位。 Bellevue Group AG 最近 13 个申报季度中有 7 个季度披露了 VRDN 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Bellevue Group AG 对 VRDN 的持仓演变
Bellevue Group AG 于 Q3 2023 首次披露 VRDN 持仓:63,770 股(约 US$978K)。 该持仓在 Q3 2026 达到峰值 7,109,318 股,市值约 US$146.4M。 在 7 次申报中,Bellevue Group AG 2 次增持、2 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 7,109,318 股、市值约 US$146.4M,环比增持 377,409 股。。 持仓曾出现大幅变动:Q4 2023 减持约 53% (随后一个季度股价下跌 20%)、Q1 2024 减持约 36% (随后一个季度股价下跌 26%)、Q1 2026 增持约 54% (随后一个季度股价下跌 6%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 63.77K | $978.23K | 新进 |
| Q4 2023 | 30.00K | $653.40K | 减持 |
| Q1 2024 | 19.10K | $334.44K | 减持 |
| Q4 2025 | 4.36M | $135.64M | 新进 |
| Q1 2026 | 6.73M | $131.56M | 增持 |
| Q2 2026 | 6.73M | $123.67M | 持有 |
| Q3 2026 | 7.11M | $146.38M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 VRDN 与 13F 数据
VRDN(VIRIDIAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 40 只申报持有 VRDN,申报仓位最大的包括:Paradigm Biocapital Advisors LP (US$227.1M), Kynam Capital Management, LP (US$126.6M), Fairmount Funds Management LLC (US$104.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 VRDN 的基金
- Paradigm Biocapital Advisors LP 12.41M 股 · $227.08M · Q3 2026
- Kynam Capital Management, LP 6.15M 股 · $126.59M · Q3 2026
- Fairmount Funds Management LLC 5.09M 股 · $104.82M · Q3 2026
- RTW INVESTMENTS, LP 4.98M 股 · $102.03M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 5.96M 股 · $81.79M · Q3 2026
- Novo Holdings A/S 4.87M 股 · $78.92M · Q3 2026
- Venrock Adviser, LLC 3.26M 股 · $67.08M · Q3 2026
- Deep Track Capital, LP 3.83M 股 · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M 股 · $61.83M · Q3 2026
- Caligan Partners LP 3.08M 股 · $57.34M · Q3 2026
- Context Capital Management, LLC 49.00M 股 · $56.47M · Q3 2026
- Avoro Capital Advisors LLC 2.50M 股 · $51.48M · Q3 2026
更多关于 Bellevue Group AG
常见问题
How long has Bellevue Group AG held VRDN?
Bellevue Group AG has disclosed VRDN holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in VRDN?
As of Q3 2026, Bellevue Group AG holds 7.11M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $146.38M, representing 3.04% of its reported portfolio and ranking #8.
Has Bellevue Group AG been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Bellevue Group AG increased its position in VRDN. The position peaked in Q3 2026 at 7.11M shares.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, Fairmount Funds Management LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.